GSK:LON
GSK plc
1Â 752,00Â GBX
arrow_upward
+0,95%(+16,50) 1 p
9. okt, 17:03:57 GMT +1 · GBX
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GSK põhistatistika genereerimine…
Ava
1Â 752,00Â GBX
Kõrge
1Â 771,50Â GBX
Madal
1Â 748,00Â GBX
Turu kapit.
92,92Â mld
Keskm. maht
5,93Â mln
Maht
6,85Â mln
Dividend
3,88%
Kvartaalne dividend
17,00Â GBX
Dividendikuupäev
13. aug 2026
Hinna ja tulu suhe
14,85
52 näd kõrgeim
2Â 282,00Â GBX
52 näd madalaim
1Â 592,00Â GBX
Aktsiatulu
1,18Â GBX
Käibivad aktsiad
4,32Â mld
Töötajate arv
67Â tuh
Ava
1Â 752,00Â GBX
Kõrge
1Â 771,50Â GBX
Madal
1Â 748,00Â GBX
Turu kapit.
92,92Â mld
Keskm. maht
5,93Â mln
Maht
6,85Â mln
Dividend
3,88%
Kvartaalne dividend
17,00Â GBX
Dividendikuupäev
13. aug 2026
Hinna ja tulu suhe
14,85
52 näd kõrgeim
2Â 282,00Â GBX
52 näd madalaim
1Â 592,00Â GBX
Aktsiatulu
1,18Â GBX
Käibivad aktsiad
4,32Â mld
Töötajate arv
67Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
The Business Journals
·
3 tunni eest
GSK commits $800M for construction of new Upper Merion facility as pharma investment surges
AD HOC NEWS
·
4 tunni eest
GSK stock trades at EUR 20.81 with USD 93.2 billion value
Yahoo Finance
·
6 tunni eest
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
Traders Union
·
7 tunni eest
Can $2.5B restructuring plan lift GSK stock?
Profiil
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Teave üksuse GSK plc kohta
TegevjuhtEmma Walmsley | Emma Walmsley
Töötajad66,8 tuh
Asutatud27. dets 2000
Peakontorid-
Sektor-
Veebisaitgsk.com